|
An internal dose-response analysis. |
||||
| ICD-10 |
Site |
Digitoxin concentration ng/ml |
||
|
|
||||
| <16 |
16–22 |
>22 |
||
|
|
||||
| C50 |
Breast |
1.00 (reference) |
1.04(0.59, 1.84) |
0.90(0.48, 1.67) |
| C61 |
Prostate |
1.00 (reference) |
0.79(0.51, 1.22) |
0.89(0.56, 1.40) |
| C18–C21 |
Colo-rectal |
1.00 (reference) |
0.97(0.66, 1.42) |
0.92(0.61, 1.40) |
| C32–C34 |
Lung |
1.00 (reference) |
1.25(0.71,2.22) |
1.06(0.57,2.00) |
| C64, C65 |
Kidney, urinary |
1.00 (reference) |
0.30(0.15,0.57) |
0.45 (0.24, 0.83) |
| C67, C68 |
organs |
|||
| C43,C44 |
Melanoma, other |
1.00 (reference) |
1.16(0.60,2.25) |
1.29(0.65,2.57) |
| skin |
||||
| C81–C85 |
Leukemia and |
1.00 (reference) |
0.67(0.38, 1.18) |
0.57(0.30, 1.08) |
| C88–C92 |
Lymphoma |
|||
| C00-C97 |
All sites |
1.00 (reference) |
0.84(0.71,0.99) |
0.86(0.72, 1.02) |
|
An internal dose-response analysis. Age-adjusted relative risks (95% confidence limits) of specific types of cancer by concentration levels (tertiles) of digitoxin. A Cox regression analysis was used. | ||||
Haux et al. BMC Cancer 2001 1:11 doi:10.1186/1471-2407-1-11 |
||||